Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE 2
NCT07225842Phase 4Recruiting
- Sponsor
- University of Florida
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cangrelor in coronary artery disease (CAD), sponsored by University of Florida. Primary endpoint: Optimal platelet reactivity. Started Feb 2026; status: recruiting.
02
Drugs
cangrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07225842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225842.